drug
eflapegrastim
Marketedupdated 3mo agoby Spectrum Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1all catalysts(0)
nothing on the calendar yet
Trials studying eflapegrastim
- phase2A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
- phase1Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
- phase4Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy
News(1)
- Assertio accepts new buyout bid; AI biotech Isomorphic banks $2BAssertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.biopharma_dive · 3mo ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that